Javascript must be enabled to use this form.

View Profile	Home Browse Faculty Facility Research Consortia Training Grants Courses Search Support About rSp Help and FAQ's Contact Us	GCC Home
Faculty Profile Last Modified Time: 01:40:53 PM Mon, 20 Apr 2020   Contact Information Kyoji Tsuchikama Associated Profiles  Assistant Professor, Institute of Molecular Medicine, UT Health Science Center at Houston     Kyoji.Tsuchikama@uth.tmc.edu     (713) 486-5431    Web Link    Lab Webpage    Cycloaddition, Iridium, Diynes, Alkynes, Ketones, Cycloaddition Reaction, Alkenylation, Chirality    Associated Profiles Professional Preparation Research and Expertise Appointments  Professional Preparation  Degree Major Institution Year  PhD Organic Chemistry Waseda University 2010  MS Organic Chemistry Waseda University 2007  BS Chemistry Waseda University 2005  Research and Expertise Research Interests   Antibody–drug conjugates (ADCs) represent an emerging class of cancer chemotherapy agents. The striking success of ADCs, as demonstrated with 4 FDA-approved ADCs and more than 60 ADCs in clinical trials, has inspired scientists and clinicians to further advance this molecular format towards effective therapeutics for cancers. ADCs enable pinpoint delivery of highly potent antitumor drugs selectively to tumor cells while avoiding healthy tissues. The ADC chemical linker between the antibody and the drug molecule critically impacts ADC potency, safety, and durability profiles. Thus, the use of proper ADC linkers is a key to successfully implement ADC-based chemotherapy. Our primary interest is in developing novel ADC linker technologies by taking advantage of the power of organic chemistry, medicinal chemistry, and chemical biology. One example is branched ADC linkers that can be equipped with multiple drug molecules. Most ADC linkers developed to date accommodate only single cytotoxic drugs. The clinical potential of such multiloading ADC linkers had remained unexplored because of the lack of efficient and versatile methods. We developed efficient methods for installing dual-loading ADC linkers in a simple and quantitative manner. Based on this success, we are currently advancing the multi-loading strategy to produce next-generation ADCs for combating the cancer drug resistance and heterogeneity. These are unsolved issues in cancer chemotherapy leading to discontinuation of medication and recurrence of malignancy. We envisage that our ADC technologies will provide innovative approaches for overcoming such unsolved issues and establish a novel technology platform providing a number of valuable additions to the current list of drug candidates for the future clinical studies.  Publications/Creative Works Click here to search for this faculty member's publications on PubMed.  Appointments Title Department / School Institution Assistant Professor Institute of Molecular Medicine UT Health Science Center at Houston

powering - The Partnership
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.